SCHEMBL2116326

SCHEMBL2116326

Cc1cc(=O)c(OCc2ccccc2)c[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.54
MAPT P10636 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
MAPK1 P28482 1/20 0.54
POLB P06746 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
NSD2 O96028 1/20 0.46
ABL1 P00519 1/20 0.46
PPARG P37231 1/20 0.46
RIN1 Q13671 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
LIPE Q05469 1/20 0.46
MAPK14 Q16539 2/20 0.45
LTA4H P09960 1/20 0.45
MAOB P27338 1/20 0.44
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2438835 0.83 NPC1 (0.50) TDP1POLBSMN1; SMN2MAOB
SCHEMBL2492367 0.80 SRD5A2 (0.52) L3MBTL1MAPTTDP1POLBSMN1; SMN2
SCHEMBL9012908 0.80 L3MBTL1 (0.43) L3MBTL1MAPTTDP1MAPK1POLB
SCHEMBL9785325 0.80 L3MBTL1 (0.43) L3MBTL1MAPTTDP1MAPK1POLB
SCHEMBL9653085 0.80 LOXL2 (0.48) L3MBTL1POLBNSD2ABL1PPARG
SCHEMBL71120 0.80 GSTP1 (0.44) L3MBTL1MAPTTDP1POLBSMN1; SMN2
SCHEMBL13462058 0.80 LMNA (0.50) L3MBTL1MAPTTDP1MAPK1POLB
SCHEMBL9012870 0.80 HTR2A (0.43) L3MBTL1MAPTTDP1MAPK1POLB
SCHEMBL10897164 0.80 L3MBTL1 (0.45) L3MBTL1MAPTTDP1POLBSMN1; SMN2
SCHEMBL2116953 0.79 L3MBTL1 (0.42) L3MBTL1MAPTTDP1MAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110218207-B Coumarin hybrid pyridone compound with iron chelation and monoamine oxidase B inhibition activity and preparation and application thereof 浙江工业大学 2020-12-25 CN disclosed
US-9938240-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX INC. (CA) 2018-04-10 US disclosed
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ APOTEX TECHNOLOGIES INC. (CA) 2017-08-31 US disclosed
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones THE BANK OF NOVA SCOTIA (CA) 2017-03-30 US disclosed
US-9550733-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX TECHNOLOGIES INC. (CA) 2017-01-24 US disclosed
EP-2134688-B1 FLUORINATED DERIVATIVES OF DEFERIPRONE APOTEX TECHNOLOGIES INC (CA) 2016-10-05 EP disclosed
US-20160083346-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones APOTEX TECHNOLOGIES INC. (CA) 2016-03-24 US disclosed
CN-103601673-B The fluorinated derivatives of 3-pyridone-4-ketone APOTEX TECHNOLOGIES INC. (CA) 2016-03-16 CN disclosed
US-20150335626-A1 FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX INC. (CA) 2015-11-26 US disclosed
US-20150274665-A1 FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES FLORIDA TURBINE TECHNOLOGIES, INC. 2015-10-01 US disclosed
EP-2448922-B1 FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX TECHNOLOGIES INC (CA) 2014-08-20 EP disclosed
CN-102712591-B Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX TECHNOLOGIES INC 2014-06-25 CN disclosed
US-8673943-B2 Fluorinated derivatives of deferiprone APOTEX TECHNOLOGIES INC. (CA) 2014-03-18 US disclosed
CN-103601673-A Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX TECHNOLOGIES INC 2014-02-26 CN disclosed
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX TECHNOLOGIES INC. (CA) 2012-10-25 US disclosed
US-20120095061-A1 Fluorinated Derivatives of Deferiprone APOTEX TECHNOLOGIES INC. (CA) 2012-04-19 US disclosed
US-8026261-B2 neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one APOTEX TECHNOLOGIES INC. (CA) 2011-09-27 US disclosed
EP-2134688-A1 FLUORINATED DERIVATIVES OF DEFERIPRONE Apotex Technologies Inc. (CA) 2009-12-23 EP disclosed
WO-2008116301-A1 FLUORINATED DERIVATIVES OF DEFERIPRONE APOTEX TECHNOLOGIES INC. (CA) 2008-10-02 WO disclosed
US-20080242706-A1 Fluorinated derivatives of deferiprone APOTEX TECHNOLOGIES INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160083346-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones FH, FECH, FPGS L3MBTL1 2478/4885MAPT 1342/4885TDP1 817/4885
US-20080242706-A1 Fluorinated derivatives of deferiprone SLC40A1, TFRC, FECH L3MBTL1 3150/4885MAPT 199/4885TDP1 703/4885
US-20150335626-A1 FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES FH, FECH, TFRC L3MBTL1 2457/4885MAPT 2056/4885TDP1 1040/4885
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES FH, FECH, FTH1 L3MBTL1 2399/4885MAPT 1822/4885TDP1 1079/4885
US-20120095061-A1 Fluorinated Derivatives of Deferiprone SLC40A1, TFRC, FECH L3MBTL1 3150/4885MAPT 199/4885TDP1 703/4885
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones FH, FECH, FPGS L3MBTL1 2228/4885MAPT 1549/4885TDP1 966/4885
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ FH, FECH, FPGS L3MBTL1 2433/4885MAPT 1732/4885TDP1 822/4885
US-20150274665-A1 FLUORINATED DERIVATIVES OF 3-HYDROXYPYRIDIN-4-ONES FH, FECH, TFRC L3MBTL1 2457/4885MAPT 2056/4885TDP1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.